Investors comparing cannabis equities often find themselves choosing between very different business models despite a shared sector label. CGC, Canopy Growth Corporation, is a Canadian producer expanding aggressively into international medical markets, while GLAS, Glass House Brands Inc., is a vertically integrated cultivator concentrated in California. This stock comparison is relevant for traders evaluating relative performance, market positioning, and risk across two companies at different stages of a broader industry recovery. Both names carry meaningful volatility and regulatory exposure, making a side-by-side look at recent momentum, catalysts, and financial trends useful for investors weighing where relative strength may be building. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Canopy Growth Corporation is one of Canada's largest cannabis producers, with brands spanning medical and adult-use products plus the Storz & Bickel vaporizer business. In recent quarters, CGC has shown improving operating momentum: consolidated revenue rose double digits year over year, led by a sharp jump in international medical sales in Germany and Poland, along with new entries into the United Kingdom and Australia. Management has pointed to a narrowing adjusted EBITDA loss and a stated goal of reaching positive adjusted EBITDA during its fiscal 2027. At the same time, the stock remains in penny-stock territory, well below its 52-week high, and dilution remains a concern after a debt-for-equity recapitalization and the acquisition of MTL Cannabis increased the share count substantially. A large non-cash fair-value charge tied to its U.S. affiliate also weighed on a recent reported net loss, underscoring the volatility in headline results.
Glass House Brands is a vertically integrated U.S. cannabis company focused on the California market, operating cultivation, manufacturing, branded consumer products, and retail dispensaries. GLAS recently uplisted to the New York Stock Exchange, a move aimed at broadening investor access. Its most recent quarter showed record biomass production of roughly 319,000 pounds and a lower cost of production, but average selling prices fell sharply amid a trim-heavy sales mix, compressing gross margin and adjusted EBITDA. Revenue expanded sequentially and year over year, yet the shares have declined steeply over the trailing 52-week period. Governance-related developments, including a planned CFO retirement, a director resignation, and a change of auditor, have added to investor caution, even as sell-side analysts maintain an overall positive stance with a price target well above the current level.
The clearest contrast between the two is geographic and structural. CGC operates across Canadian medical and adult-use markets while rapidly scaling a higher-margin international medical export business, giving it diversified demand drivers but also exposing it to share-dilution and U.S. affiliate risks. GLAS offers scale and low-cost cultivation in California, yet its fortunes hinge heavily on wholesale biomass pricing, which has weakened as its product mix shifted toward lower-value trim. On momentum, CGC's revenue growth and narrowing losses appear more consistent, while GLAS's record production has not yet translated into improved profitability. Both face sector-wide catalysts, including evolving U.S. rescheduling and legalization progress, but they are at different stages of execution on the path toward sustainable profitability. From what I see, this is important because it highlights how execution differences can matter more than sector tailwinds alone.
Based on observable factors such as trend consistency, relative positioning, and near-term catalysts, Tickeron's AI would currently lean toward CGC. The preference reflects Canopy Growth's steadier revenue growth, improving adjusted EBITDA trajectory, and expanding international medical footprint, contrasted with Glass House Brands' compressing price mix, margin pressure, and governance-related uncertainty. That said, this is a probabilistic assessment rather than a definitive forecast: both stocks carry elevated risk, and sentiment in the cannabis sector can shift quickly with regulatory developments. Traders should weigh these signals alongside their own research and risk tolerance. I’m watching this closely as the sector evolves.
I often turn to Tickeron’s Trending AI Robots when comparing names like these. The platform curates hundreds of AI trading bots, each with its own style and performance history, selecting only the strongest performers for current conditions. This gives me a data-driven way to spot strategies that align with my risk tolerance without relying solely on manual analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CGC saw its Momentum Indicator move below the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 76 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CGC turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 38 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CGC entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGC advanced for three days, in 162 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (6.379). P/E Ratio (-0.972) is within average values for comparable stocks, (0.548). CGC's Projected Growth (PEG Ratio) (7.200) is slightly higher than the industry average of (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.549) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a producer of medical marijuana
Industry PharmaceuticalsGeneric